These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23895135)

  • 1. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.
    Jardim DL; Conley A; Subbiah V
    Orphanet J Rare Dis; 2013 Jul; 8():112. PubMed ID: 23895135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
    Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
    Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
    Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
    Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
    Gatalica Z; Vranic S; Ghazalpour A; Xiu J; Ocal IT; McGill J; Bender RP; Discianno E; Schlum A; Sanati S; Palazzo J; Reddy S; Pockaj B
    Oncotarget; 2016 Jan; 7(2):1707-16. PubMed ID: 26625196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of pleomorphic liposarcomatous differentiation in malignant phyllodes tumor of the breast: A case report.
    Zhou P; Zhang Q; Zhu J; Li P
    Pathol Res Pract; 2021 Aug; 224():153489. PubMed ID: 34091389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phyllodes tumors of the breast segregate in two groups according to genetic criteria.
    Laé M; Vincent-Salomon A; Savignoni A; Huon I; Fréneaux P; Sigal-Zafrani B; Aurias A; Sastre-Garau X; Couturier J
    Mod Pathol; 2007 Apr; 20(4):435-44. PubMed ID: 17334353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
    Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
    Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic characteristics of two breast malignant phyllodes tumors during pregnancy and lactation identified through whole-exome sequencing.
    Lei T; Shen M; Deng X; Shi Y; Peng Y; Wang H; Chen T
    Orphanet J Rare Dis; 2022 Oct; 17(1):382. PubMed ID: 36271373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic profiling by array comparative genomic hybridization reveals novel DNA copy number changes in breast phyllodes tumours.
    Kuijper A; Snijders AM; Berns EM; Kuenen-Boumeester V; van der Wall E; Albertson DG; van Diest PJ
    Cell Oncol; 2009; 31(1):31-9. PubMed ID: 19096148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression.
    Kersting C; Kuijper A; Schmidt H; Packeisen J; Liedtke C; Tidow N; Gustmann C; Hinrichs B; Wülfing P; Tio J; Boecker W; van Diest P; Brandt B; Buerger H
    Lab Invest; 2006 Jan; 86(1):54-61. PubMed ID: 16258523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative genomic analysis of primary tumors and metastases in breast cancer.
    Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
    Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of SDHB and NF1 genes in a malignant phyllodes tumor of the breast as detected by oligo-array comparative genomic hybridization.
    Lee J; Wang J; Torbenson M; Lu Y; Liu QZ; Li S
    Cancer Genet Cytogenet; 2010 Jan; 196(2):179-83. PubMed ID: 20082856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study.
    Lv S; Niu Y; Wei L; Liu Q; Wang X; Chen Y
    Breast Cancer Res Treat; 2008 Dec; 112(3):411-8. PubMed ID: 18189161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis.
    Egas-Bejar D; Anderson PM; Agarwal R; Corrales-Medina F; Devarajan E; Huh WW; Brown RE; Subbiah V
    Oncoscience; 2014 Mar; 1(2):167-179. PubMed ID: 25126591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-genome profiling helps to classify phyllodes tumours of the breast.
    Laé M; La Rosa P; Mandel J; Reyal F; Hupé P; Terrier P; Couturier J
    J Clin Pathol; 2016 Dec; 69(12):1081-1087. PubMed ID: 27207013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular assessment of clonality leads to the identification of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma.
    Bot FJ; Sleddens HF; Dinjens WN
    Diagn Mol Pathol; 1998 Dec; 7(6):295-301. PubMed ID: 10207667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic landscapes of breast fibroepithelial tumors.
    Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
    Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
    Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
    Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
    Ng CC; Tan J; Ong CK; Lim WK; Rajasegaran V; Nasir ND; Lim JC; Thike AA; Salahuddin SA; Iqbal J; Busmanis I; Chong AP; Teh BT; Tan PH
    J Clin Pathol; 2015 Sep; 68(9):685-91. PubMed ID: 26018969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups.
    Tan WJ; Lai JC; Thike AA; Lim JC; Tan SY; Koh VC; Lim TH; Bay BH; Tan MH; Tan PH
    Breast Cancer Res Treat; 2014 Jun; 145(3):635-45. PubMed ID: 24831776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.